Close

Moody's places Teva'S (TEVA) Baa3 ratings on review for downgrade

December 14, 2017 12:56 PM EST

Moody's Investors Service, placed the Baa3 senior unsecured ratings of Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) and its subsidiaries under review for downgrade.

Moody's took the following actions on Teva Pharmaceutical Industries Ltd and subsidiaries:

Ratings placed on review for downgrade:

Issuer rating at Baa3

Backed Senior unsecured rating at Baa3

Senior unsecured shelf at (P)Baa3

Backed Senior unsecured shelf at (P)Baa3

RATINGS RATIONALE

Teva faces significant challenges to sustainably reduce its financial leverage to levels acceptable for its current rating over the next couple of years. Earnings declines in Copaxone will be significant, potentially exceeding lost earnings that Moody's had earlier anticipated. At the same time, weakness in the US generics business will weigh on Teva for at least the next two years. Moody's recognizes that Teva's announced restructuring plan resulting in drastic cost cuts and a suspension of its dividend are credit positive. However the company has now said that it will not consider other actions -- such as equity raises. Moody's review will focus on (1) the timing and execution risk of achieving $3 billion in cost savings; (2) the potential negative ramifications of drastic cost cuts on things such as R&D productivity and quality control ; and (3) the impact of the restructuring on cash flows and leverage through 2019.

Teva's Baa3 rating (under review for downgrade) reflects its significant scale, global diversity, and position as the world's largest generic drug company, as well as one of the largest manufacturers of active pharmaceutical ingredients. It is also supported by strong, albeit declining, cash flow. The rating is constrained by Teva's high financial leverage and high profit concentration in Copaxone.

Headquartered in Petah Tikvah, Israel, Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company offering a mix of generic and branded products. Reported revenue for the twelve months ended September 30, 2017 was approximately $23.4 billion.

The principal methodology used in these ratings was that for the Pharmaceutical Industry published in June 2017. Please see the Rating Methodologies page on www.moodys.com for a copy of this methodology.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Credit Ratings

Related Entities

Moody's Investors Service, Earnings